GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
(1 ) 1000 L- L-,
Journal of the American Academy of Dematology, 42 , 640644
The most common side effects are gastrointestinal: nausea (especially during dose increases), occasional vomiting, diarrhea, constipation, and abdominal discomfort
19. Sargen MR, Merrill SL, Chu EY & Nathanson KL
